← Back

Shenzhen Salubris Pharmaceuticals Co Ltd

Shenzhen Salubris Pharmaceuticals Co., Ltd. researches, develops, produces, and sells pharmaceuticals and medical devices in China. Its pharmaceutical products target chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. The company also develops, produces, and sells high-end interventional medical devices, including those for cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. Incorporated in 1998 and headquartered in Shenzhen, China, it operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.

Price · split & dividend adjusted
News & notes moving 002294.CS
002294.CS

Salubris Releases 2026 Interim Report with Net Profit of 387 Million Yuan

Salubris released its 2026 interim report on August 25, 2026. Total operating revenue was 2.479 billion yuan, net profit attributable to the parent company was 387 million yuan, and net operating cash inflow was 466 million yuan. The company's latest asset-liability ratio was 21.52 percent, up 2.80 percentage points from the previous quarter and up 3.40 percentage points from the same period last year. The latest gross margin was 75.09 percent, down 1.49 percentage points from the previous quarter and down 0.22 percentage points from the same period last year. The latest return on equity was 4.52 percent, and diluted earnings per share was 0.35 yuan. The company's latest total asset turnover was 0.22 times, inventory turnover was 1.11 times, the number of shareholders was 74,100, and the top ten shareholders held 739 million shares, accounting for 66.25 percent of total share capital.
002294.CS
Jiemian·25dRead more →
Biotech & Genomic Medicine▲3

Salubris' Class 1 Innovative Drug SAL012 for Injection Accepted for Clinical Trial Application

Shenzhen Salubris Pharmaceuticals announced that its self-developed Class 1 innovative drug SAL012 for injection has been accepted for clinical trial application by the National Medical Products Administration, intended for the treatment of advanced solid tumors. The drug is registered as a Class 1 therapeutic biological product, with acceptance number CXSL2600858. Preclinical studies have shown it has the potential to inhibit tumor growth in a dose-dependent manner, with good safety and tolerability. According to regulations, if no negative or questioning opinions are received from the Center for Drug Evaluation within 60 days from the date of acceptance, the applicant may conduct clinical trials according to the submitted protocol. The company cautioned that drug development involves a long cycle and high risks, and will not have a material impact on its performance in the short term.
002294.CS ▲
Biotech & Genomic Medicine
Jiemian·35dRead more →
© 2026 MarketDXAsset